Healthcare >> CEO Interviews >> April 18, 2005
STEPHEN M. CHANG is President of MultiCell Technologies, Inc. Dr. Chang
is also CEO of privately held Astral Therapeutics, a San Diego
biotechnology company developing novel therapies for diabetes and other
autoimmune diseases. Dr Chang is also President of CURES
(www.curescalifornia.org) a coalition of patient advocates,
biotechnology companies, pharmaceutical companies and venture
capitalists dedicated to ensuring the safety, research and development
of innovative life saving medications. Dr Chang is also an active Board
member of BIOCOM, San Diego's premier life sciences organization. Dr.
Chang was Chief Science Officer and Vice President of Canji
Inc./Schering Plough Research Institute in San Diego from 1998 to 2004,
managing four large external biotech corporate partnerships with
Transgene, Myriad Genetics, Genzyme and Immune Response. Dr. Chang had
responsibility for development of a strategic plan for patents and an
overall strategic plan, plus representing research efforts to external
corporate partners, to the FDA and to the academic community. From 1995
to 1997, Dr. Chang was Director of Research for Chiron Viagene, and
Chiron Inc., where he headed four research departments: genetic
programs, viral therapeutics and delivery, cancer therapeutics and gene
transfer immunology and immunobiology. From 1988 to 1995, Dr. Chang
served as Director, Viral and Genetic Therapeutics and Senior Principal
Scientist for Viagene, Inc. Dr. Chang earned his Doctoral degree in
Biological Chemistry, Molecular Biology and Biochemistry from the
University of California, Irvine. He has filed more than 40 patents
worldwide and is extensively published. Profile
Technologies and a picture of what you are doing at the present time?
Dr. Chang: MultiCell is a company that is a result of a
